In addition, the NGS study did not reveal the presence of new mutations, as the variants observed at CP-CML (TET2 and DNMT3A) remained unchanged at BP-CML with similar VAF. This evidence concerns the gene TET2 and chronic myelogenous leukemia, BCR-ABL1 positive.